CHEMNAVIGATOR'S IRESEARCH™ LIBRARY EXCEEDS 10 MILLION SAMPLES USED IN DRUG DISCOVERY

iResearch Library now accessible through new 3-DPL™ Map virtual screening collaborations.

ChemNavigator announced today that its iResearch Library has grown to include over 10 million chemical samples from over 100 commercial, government, and academic supplier sources around the world.

The iResearch Library is the most up-to-date compilation of commercially accessible drug-like compounds available for pharmaceutical research and currently tracks over 10 million chemical samples. Over 1 million sample records each month are processed including, additions of new chemistry, reconfirmation of existing offerings, and removal of unavailable chemistry. Scientists search through the iResearch Library and identify drug-like compounds they can use in their research at a fraction of the time and cost of synthesizing those compounds within their own laboratory.

As part of ChemNavigator's ChemMatrix™ suite of products, the iResearch Library may be accessed through annual subscription via the on-line iResearch System or structure files on CD/DVD ROM. Subscriptions include access to regular updates, sample sourcing information, and ChemNavigator's optional Chemistry Procurement Service. Subscriptions to the iResearch Library eliminate a pharmaceutical or agrochemical research organization's need to aggregate and maintain information about the constantly changing inventory of research compounds that are available from worldwide chemistry sources.

ChemNavigator is expanding the commercial access to the iResearch Library to include virtual screening services. With ChemNavigator's new 3-dimensional protein-ligand mapping technology (3-DPL™ Map) ChemNavigator scientists can select chemical libraries designed to contain compounds with high biological affinity for a partner's drug target. In addition, as new chemical samples are registered into the iResearch Library, 3-DPL Map evaluates each sample structure for potential binding affinity to the research partner's drug target.

"The growth and accuracy of the iResearch Library provides ChemNavigator a vast pool of drug-like chemistry to draw upon for our virtual screening collaboration partners," comments Dr. Tad Hurst, chief technical officer for ChemNavigator. "With 3-DPL Map, we can screen in silico the entire iResearch Library against a partner's drug target in a few days."

Over the past 2.5 years, Dr. Hurst's research group at ChemNavigator has developed and filed patents around 3-DPL Map technology. 3-DPL Map has been scientifically validated through comparison of 3-DPL Map results with experimentally determined co-crystallized ligand binding studies.

About ChemNavigator, Inc.
ChemNavigator is a privately held biotechnology company focused on drug discovery using our proprietary proteomics and cheminformatics technologies, called 3-DPL Map and ChemMatrix. Our competitive advantage is our unique ability to identify and analyze, with unmatched speed, the biochemical relationships that exist between a potential drug compound and its entire drug target molecule. Our 3-DPL Map technology allows for more efficient and cost effective drug discovery by providing the ability to screen tens of millions of potential drugs in silico in order to rapidly identify compounds with a high likelihood of showing favorable activity. Our ChemMatrix technology is employed within products and services used by over 40 pharmaceutical and biotechnology companies to perform cost effective new drug discovery.